Circulating microparticle proteins predict pregnancies complicated by placenta accreta spectrum

Area of Science:

• Obstetrics and Gynecology
• Maternal-Fetal Medicine
• Biomarker Discovery

Background:

• Placenta accreta spectrum (PAS) involves abnormal placental attachment, risking severe maternal hemorrhage during delivery.
• Current diagnostic methods for PAS are insufficient, leading to approximately 50% of cases being undiagnosed prenatally.
• Early and accurate diagnosis is crucial for multidisciplinary delivery planning and improving maternal outcomes.

Purpose of the Study:

• To identify circulating microparticle (CMP) protein panels capable of diagnosing pregnancies complicated by PAS.
• To evaluate the diagnostic performance of CMP protein panels in different gestational trimesters.

Main Methods:

• A nested case-control study involving 35 PAS cases and 70 controls.
• Size exclusion chromatography and liquid chromatography-tandem mass spectrometry for CMP protein isolation and identification.
• A two-step iterative workflow to establish diagnostic protein panels.

Main Results:

• Five CMP proteins distinguished PAS from controls with an AUC of 0.83 at a median of 26 weeks' gestation.
• A separate panel achieved an AUC of 0.78 at a median of 35 weeks' gestation.
• Second-trimester analysis indicated over-representation of iron homeostasis and erythropoietin signaling pathways; third-trimester analysis revealed abnormal immune function.

Conclusions:

• Circulating microparticle protein panels show significant potential for diagnosing PAS well before delivery.
• This diagnostic approach could substantially reduce maternal morbidity and mortality associated with PAS.
• Further research into CMP protein panels may lead to improved prenatal screening for PAS.